Equity Profile

ROIV

Roivant Sciences Ltd.

Health CareBiotechnology$26.2B

Aug10Mon

Pre-Earnings Brief

UpcomingQ1-2026Pre-Market9:00 AM EDT

Company Snapshot

Roivant Sciences Ltd. is a biotechnology company focused on developing innovative therapies to improve patient outcomes....

Key Metrics to Watch

EPS

Earnings per share is a key measure of profitability and will indicate how well the company is managing its expenses relative to revenue.

$-0.45

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$3M

Wall Street expectations, options signals, track record, and call prep available with Pro.

ROIV Q1-2026 Earnings Preview

Context

Company Snapshot

Roivant Sciences Ltd. is a biotechnology company focused on developing innovative therapies to improve patient outcomes. Operating in the health care sector, Roivant is known for its unique approach to drug development and commercialization, which aims to address unmet medical needs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+61.93%

Avg Stock Reaction

+5.96%

Last Quarter Recap

In the last quarter, Roivant reported an EPS of $0.28, significantly beating analyst expectations. The stock reacted positively, gaining nearly 15% the following day.

Management Promises & Guidance

Continued focus on pipeline development and potential new drug launches.
Commitment to improving operational efficiency.
Plans to expand partnerships to enhance research capabilities.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Roivant's upcoming earnings, with expectations for a narrower loss than in previous quarters. The company has shown a tendency to beat estimates recently, which could bolster investor confidence.

Bull Case

If Roivant can deliver better-than-expected revenue and demonstrate progress in its drug pipeline, it may see a significant stock price increase, reflecting strong investor sentiment.

Bear Case

Conversely, if the company fails to meet its revenue expectations or reports wider losses, it could lead to a sharp decline in stock price, as investors may lose confidence in its growth strategy.

Key Metrics to Watch

EPS

$-0.45

Earnings per share is a key measure of profitability and will indicate how well the company is managing its expenses relative to revenue.

Revenue

$3M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Roivant's revenue meet or exceed the $3M consensus estimate?

Achieving or surpassing this revenue target could signal strong market demand and operational effectiveness, which is crucial for investor confidence.

How does management plan to address the expected EPS of $-0.45?

Understanding the company's strategy to reduce losses will be key for investors assessing the sustainability of Roivant's business model.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Roivant's potential for revenue growth due to its recent successful drug developments and partnerships.

Supporting Evidence

The company has shown a consistent ability to beat EPS estimates in recent quarters.

Options pricing suggests a significant move, indicating that investors are anticipating a more volatile outcome than the consensus reflects.

Key Risk

If revenue comes in below $3M, it could undermine the positive outlook and lead to a reassessment of the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will reflect Roivant's ability to manage costs while growing its revenue base amid ongoing development efforts.

Bull Confirmed If

Revenue exceeding $3M and a narrower EPS loss than expected would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-0.45 and revenue falling short of $3M would validate the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±10.0%

Historical Avg

±7.2%

Pricing rich

The options market is pricing in a significant move around the earnings report, suggesting that investors expect volatility based on the results.

Options are pricing ±10.0% while ROIV has averaged ±7.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

51.6%

Calls (5K)P/C Ratio: 0.18Puts (1K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Roivant beats expectations, history suggests a potential stock increase of around 9.1%, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience moderate movement, reflecting cautious investor sentiment.

Miss

Should Roivant miss expectations, the stock could decline by about 0.7%, indicating a loss of confidence in the company's growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments or partnerships.
2Management's commentary on cost management strategies.
3Insights into market demand for Roivant's products.
4Details on operational efficiencies and future guidance.
5Responses to analyst questions regarding competitive positioning.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug7

PAABMO

Plains All American Pipeline, L.P.

PreviewView

Aug7

ESNTBMO

Company Snapshot

Roivant Sciences Ltd. is a biotechnology company focused on developing innovative therapies to improve patient outcomes....

Key Metrics to Watch

EPS

Earnings per share is a key measure of profitability and will indicate how well the company is managing its expenses relative to revenue.

$-0.45

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$3M

Wall Street expectations, options signals, track record, and call prep available with Pro.

ROIV Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+61.93%

Avg Stock Reaction

+5.96%

Last Quarter Recap

In the last quarter, Roivant reported an EPS of $0.28, significantly beating analyst expectations. The stock reacted positively, gaining nearly 15% the following day.

Management Promises & Guidance

Continued focus on pipeline development and potential new drug launches.
Commitment to improving operational efficiency.
Plans to expand partnerships to enhance research capabilities.

Expectations

Wall Street Expectations

Bull Case

If Roivant can deliver better-than-expected revenue and demonstrate progress in its drug pipeline, it may see a significant stock price increase, reflecting strong investor sentiment.

Bear Case

Conversely, if the company fails to meet its revenue expectations or reports wider losses, it could lead to a sharp decline in stock price, as investors may lose confidence in its growth strategy.

Key Metrics to Watch

EPS

$-0.45

Earnings per share is a key measure of profitability and will indicate how well the company is managing its expenses relative to revenue.

Revenue

$3M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Roivant's revenue meet or exceed the $3M consensus estimate?

Achieving or surpassing this revenue target could signal strong market demand and operational effectiveness, which is crucial for investor confidence.

How does management plan to address the expected EPS of $-0.45?

Understanding the company's strategy to reduce losses will be key for investors assessing the sustainability of Roivant's business model.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Roivant's potential for revenue growth due to its recent successful drug developments and partnerships.

Supporting Evidence

The company has shown a consistent ability to beat EPS estimates in recent quarters.

Options pricing suggests a significant move, indicating that investors are anticipating a more volatile outcome than the consensus reflects.

Key Risk

If revenue comes in below $3M, it could undermine the positive outlook and lead to a reassessment of the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will reflect Roivant's ability to manage costs while growing its revenue base amid ongoing development efforts.

Bull Confirmed If

Revenue exceeding $3M and a narrower EPS loss than expected would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-0.45 and revenue falling short of $3M would validate the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±10.0%

Historical Avg

±7.2%

Pricing rich

The options market is pricing in a significant move around the earnings report, suggesting that investors expect volatility based on the results.

Options are pricing ±10.0% while ROIV has averaged ±7.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

51.6%

Calls (5K)P/C Ratio: 0.18Puts (1K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Roivant beats expectations, history suggests a potential stock increase of around 9.1%, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience moderate movement, reflecting cautious investor sentiment.

Miss

Should Roivant miss expectations, the stock could decline by about 0.7%, indicating a loss of confidence in the company's growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments or partnerships.
2Management's commentary on cost management strategies.
3Insights into market demand for Roivant's products.
4Details on operational efficiencies and future guidance.
5Responses to analyst questions regarding competitive positioning.